TXTM (ProText Mobility) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2014)


What is ProText Mobility ROE % Adjusted to Book Value?

ProText Mobility TXTM -3.00% ROE % Adjusted to Book Value is 0.00% as of Sep. 2014.

ProText Mobility's ROE % for the quarter that ended in Sep. 2014 was 0.00%. ProText Mobility's PB Ratio for the quarter that ended in Sep. 2014 was N/A. ProText Mobility's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2014 was N/A.

ProText Mobility ROE % Adjusted to Book Value Related Terms

ProText Mobility ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for ProText Mobility's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProText Mobility ROE % Adjusted to Book Value Chart

ProText Mobility Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ProText Mobility Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TXTM vs DRSV, YPPN, CYBF: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, ProText Mobility's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProText Mobility ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProText Mobility's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ProText Mobility's ROE % Adjusted to Book Value falls into.


ProText Mobility ROE % Adjusted to Book Value Calculation

ProText Mobility's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2013 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

ProText Mobility's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2014 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
ProText Mobility (TXTM) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2014. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ProText Mobility and its competitors.
Is ProText Mobility's ROE % Adjusted to Book Value too high?
ProText Mobility's current ROE % Adjusted to Book Value is 0.00%.
How does ProText Mobility's ROE % Adjusted to Book Value compare to DRSV and YPPN?
ProText Mobility's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ProText Mobility and its competitors. ProText Mobility's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProText Mobility stock overvalued right now?
ProText Mobility (TXTM) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ProText Mobility (TXTM), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProText Mobility Business Description

Address One West Las Olas Boulevard, Suite 500, Fort Lauderdale, FL, USA, 33301
ProText Mobility Inc is a Biotech Company developing a Hemp/CBD-Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes and technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products, all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.